The linked FDA records tie this applicant to one approved device family: Bausch + Lomb Ultra (samfilcon A) Contact Lenses, regulated as soft contact lenses for extended wear under 21 CFR 886.5925 in the ophthalmic specialty. The original premarket approval, P170035, carries a decision date of April 30, 2018, and the later supplement P170035/S021 carries a decision date of September 14, 2026. Both entries list the applicant as Bausch and Lomb, Inc., at 1400 N. Goodman St., Rochester, NY, which is the address in the filing rather than a verified corporate headquarters. [1][2][5]

The approved device and its stated indications

The Summary of Safety and Effectiveness Data identifies the device generically as a samfilcon A soft (hydrophilic) contact lens, trade name Bausch + Lomb ULTRA (samfilcon A) Contact Lenses, product code LPM, with FDA notice of approval dated April 30, 2018. The same document states that CDRH issued an approval order on that date and that the applicant's manufacturing facilities were inspected and found in compliance with the Quality System regulation at 21 CFR 820. [5]

The indications recorded in the approval record describe single vision spherical correction for extended wear of up to 7 days between removals for cleaning and disinfection or disposal, as recommended by the eye care practitioner, for refractive ametropia in aphakic and/or not-aphakic persons with non-diseased eyes. A separate astigmatism indication covers correction of refractive ametropia including astigmatism up to 5.00 diopters, and the record notes add powers from +0.75D to +5.00D. [2]

The 2026 supplement and its scope

Supplement P170035/S021 is recorded as a 30-Day Notice with decision code OK30 and decision date September 14, 2026, received August 17, 2026. Its supplement reason is a process change affecting manufacturer, sterilizer, packager or supplier, and the applicant's statement describes expansion and relocation of the monomer mix manufacturing area at the Rochester, NY manufacturing facility. The expedited review flag is recorded as N. [1]

The FDA database entry for P170035 notes that the device has supplements and that the device description or indication may have changed, directing readers to the supplements for current information. The supplied supplement record documents a manufacturing-area change; it does not state any change to the indications summarized above. [3][1]

How the supplied collection is organized

The MedtechLedger snapshot contains two linked premarket approval records, both on the PMA pathway. Across the full collection, decision counts are one OK30 and one APPR; within the explicitly smaller record sample of two rows, the sample decision counts are likewise one OK30 and one APPR. These figures describe the supplied filings as of the snapshot date and are not measures of total company sales, total portfolio or safety performance. [1][2]

The two rows map to distinct filings: the APPR row is P170035 with decision date April 30, 2018, and the OK30 row is P170035/S021 with decision date September 14, 2026. No recall records appear in the supplied sample. [1][2]

Brand material and what it does not establish

Bausch + Lomb's eye care professional site lists ULTRA Monthly among its spherical products alongside INFUSE One-Day, Biotrue ONEday, and toric, multifocal and presbyopia variants, and states that its information pertains to the U.S. only unless otherwise indicated. A consumer-facing page describes ULTRA Monthly lenses as approved for daily and extended wear of up to 7 days and makes moisture and parameter-comparison statements attributed to Bausch + Lomb. [6][8][10]

Those pages are published by the brand and are separate from the FDA filings. The linked FDA records do not establish a parent company, ownership structure, corporate website, customer list or commercial availability beyond what the cited pages state, and none of those points should be inferred from the filing address. [6][10]